Challenges of prescribing low-dose drug therapy for older people

CMAJ. Canadian Medical Association Journal

Volumn 160, Issue 7, 1999, Pages 1029-1031

  Rochon, Paula A ^a,b,d   Clark, Jocalyn P ^a   Gurwitz, Jerry H ^c  

^a Kunin Lunenfeld Applied Research Unit and Department of Food and Nutrition Services and Baycrest Centre for Geriatric Care   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d BAYCREST CENTRE FOR GERIATRIC CARE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HYDROCHLOROTHIAZIDE; METOPROLOL; THIAZIDE DIURETIC AGENT; WARFARIN;

ADVERSE DRUG REACTION; AGED; CASE REPORT; DOSE RESPONSE; DRUG DOSE; FEMALE; GERIATRICS; GOUT; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOKALEMIA; MALE; ORAL DRUG ADMINISTRATION; PILL; PRESCRIPTION; SHORT SURVEY;

EID: 0033528639     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (34)

1. Gurwitz JH, Avorn J. The ambiguous relation between aging and adverse drug reactions. Ann Intern Med 1991;114(11):956-66.
2. Nolan L, O'Malley K. Prescribing for the elderly. Part I: Sensitivity of the elderly to adverse drug reactions. J Am Geriatr Soc 1988;36:142-9.
3. Domecq C, Naranjo CA, Ruiz I, Busto U. Sex-related variations in the frequency and characteristics of adverse drug reactions. Int J Clin Pharmacol 1980;18:326-6.
4. Meyers MG, Gryfe CI, Haynes RB, Leenen FHH, Ogilvie RI. Guidelines for the treatment of uncomplicated hypertension. Toronto: Publications Ontario; 1995. p. 1-28.
5. Varden S, Mehrotra KG, Mookherjee S, Willsey GA, Gens JD, Green DE. Efficacy and reduced metabolic side effects of a 15-mg chlorothalidone formulation in the treatment of mild hypertension. JAMA 1987;258:484-8.
6. McVeigh G, Galloway D, Johnston D. The case for low dose diuretics in hypertension: comparison of low and conventional doses of cyclopenthiazide. BMJ 1988;297:95-8.
7. Johnston GD, Wilson R, McDermott BJ, McVeigh GE, Duffin D, Logan J. Low-dose cyclopenthiazide in the treatment of hypertension: a one-year community-based study. Q J Med 1991;78(286):135-43.
8. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-Hypertension). Lancet 1991;338:1281-5.
9. Carlsen JE, Kober L, Torp-Pedersen C, Johansen R. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ 1990;300:975-8.
10. The sixth report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997;157: 2413-46.
11. Col N, Fanale JE, Kronholm P. The role of medication noncompliance and adverse drug reactions in hospitalizations in the elderly. Arch Intern Med 1990;150:841-5.
12. Grymonpre RE, Mitenko PA, Sitar DS, Aoki FY, Montgomery PR. Drug associated hospital admissions in older medical patients. J Am Geriatr Soc 1988;36:1092-8.
13. Wikstrand J, Westergren G, Berglund G, Bracchetti D, Van Couter A, Feldstein CA, et al. Antihypertensive treatment with metoprolol or hydrochlorothiazide in patients aged 60 to 75 years. JAMA 1986;255(10):1304-10.
14. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. JAMA 1988;260(14):2088-93.
15. Hjalmarson A, Herlitz J, Holmberg S, Ryden L, Swedberg K, Vedin A, et al. The Goteborg metoprolol trial: effects on mortality and morbidity in acute myocardial infarction. Circulation 1983;67(Suppl I):I-26-I-32.
16. Aronow WS. Prevalence of use of beta-blockers and of calcium channel blockers in older patients with prior myocardial infarction at the time of admission to a nursing home. J Am Geriatr Soc 1996;44:1075-7.
17. Fishkind D, Paris BEC, Aronow WS. Use of digoxin, diuretics, beta blockers, angiotensin-converting enzyme inhibitors, and calcium channel blockers in older patients in an academic hospital-based geriatrics practice. J Am Geriatr Soc 1997;45:809-12.
18. Soumerai SB, McLaughlin TJ, Spiegelman D, Hertzmark E, Thibault G, Goldman L. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA 1997;277(2):115-21.
19. Shand DG. How should the proper dose of a beta blocker be determined? Circulation 1983;67(Suppl I):I-86-I-88.
20. Forman DE, Bernai JLG, Wei JY. Management of acute myocardial infarction in the very elderly. Am J Med 1992;93:315-26.
21. Wilcox RG, Roland JM, Banks DC, Hampton JR, Mitchell JRA. Randomised trial comparing propranolol with atenolol in immediate treatment of suspected myocardial infarction. BWJ 1980;280:885-8.
22. Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981;304(14):801-7.
23. Beta Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. JAMA 1982;247(12): 1707-14.
24. Gurwitz JH, Col NF, Avorn J. The exclusion of the elderly and women from clinical trials in acute myocardial infarction. JAMA 1992;268(11):1417-22.
25. Rochon PA, Fortin PR, Dear KBG, Minaker KL, Chalmers TC. Reporting of age data in clinical trials of arthritis: deficiencies and solutions. Arch Intern Med 1993;153:243-8.
26. Trimble EL, Carter CL, Cain D, Freidlin B, Ungerleider RS, Friedman MA. Representation of older patients in cancer treatment trials. Cancer Suppl 1994; 74(7):2208-14.
27. Bugeja G, Kumar A, Banerjee AK. Exclusion of elderly people from clinical research: a descriptive study of published reports. BMJ 1997;315:1059.
28. Semla TP, Beizer JL, Higbee MD. Geriatric dosage handbook. 3rd ed. Hudson (OH): Lexi-Comp, Inc; 1997.
29. Hylek EM, Skates SJ, Sheenhan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996;335(8):540-6.
30. European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995;333(1):5-10.
31. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: stroke prevention in atrial fibrillation III randomised clinical trial. Lancet 1996;348:633-8.
32. Gurwitz JH, Monette J, Rochon PA, Eckler MA, Avorn J. Atrial fibrillation and stroke prevention with warfarin in the long-term care setting. Arch Intern Med 1997;157:978-84.
33. McCrory DC, Matchar DB, Samsa G, Sanders LL, Pritchett ELC. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med 1995;155:277-81.
34. Monette J, Gurwitz JH, Rochon PA, Avorn J. Physician attitudes concerning warfarin for stroke prevention in atrial fibrillation: results of a survey of long-term care practitioners. J Am Geriatr Soc 1997;45:1060-5.